A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease

L Zhang, Y Gao, S Li, H Zhao, M Zhang, Y Yu… - International Journal of …, 2024 - Springer
Relapsed and refractory (R/R) idiopathic multicentric Castleman disease (iMCD) is a clinical
challenge with no standard treatment. In this preliminary clinical trial, we investigated the …
被引用次数：1 相关文章

A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease

L Zhang, YH Gao, SY Li, H Zhao… - International journal … - pubmed.ncbi.nlm.nih.gov
Relapsed and refractory (R/R) idiopathic multicentric Castleman disease (iMCD) is a clinical
challenge with no standard treatment. In this preliminary clinical trial, we investigated the …

A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease.

L Zhang, YH Gao, SY Li, H Zhao, MY Zhang… - International Journal …, 2024 - europepmc.org
Relapsed and refractory (R/R) idiopathic multicentric Castleman disease (iMCD) is a clinical
challenge with no standard treatment. In this preliminary clinical trial, we investigated the …